CARA

Cara Therapeutics, Inc.

0.28 USD
+0.00 (+1.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cara Therapeutics, Inc. stock is down -58.24% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.64% of the previous 10 June’s closed higher than May. 0% of analysts rate it a buy.

About Cara Therapeutics, Inc.

Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)

  • Canaccord Genuity
    Thu Jun 13, 08:58
    hold
    downgrade
  • HC Wainwright & Co.
    Thu Jun 13, 06:21
    hold
    downgrade
  • Needham
    Thu Jun 13, 06:06
    hold
    downgrade